206 related articles for article (PubMed ID: 22075408)
1. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Panzer S; Sunder-Plassmann R; Mannhalter C; Steiner S
Int J Cardiol; 2013 Jun; 166(1):126-31. PubMed ID: 22075408
[TBL] [Abstract][Full Text] [Related]
2. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
Gremmel T; Kopp CW; Moertl D; Seidinger D; Koppensteiner R; Panzer S; Mannhalter C; Steiner S
Thromb Res; 2012 May; 129(5):616-22. PubMed ID: 22154242
[TBL] [Abstract][Full Text] [Related]
3. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
4. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
5. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
6. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
12. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting.
Toma C; Zahr F; Moguilanski D; Grate S; Semaan RW; Lemieux N; Lee JS; Cortese-Hassett A; Mulukutla S; Rao SV; Marroquin OC
Am J Cardiol; 2012 Apr; 109(8):1148-53. PubMed ID: 22277895
[TBL] [Abstract][Full Text] [Related]
13. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
15. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
[TBL] [Abstract][Full Text] [Related]
16. A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Int J Cardiol; 2012 Oct; 160(2):109-13. PubMed ID: 21546102
[TBL] [Abstract][Full Text] [Related]
17. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation.
Nakata T; Miyahara M; Nakatani K; Wada H; Tanigawa T; Komada F; Hoshino K; Aoki T; Nishimura Y; Tamaru S; Ito M; Nishikawa M;
Circ J; 2013; 77(6):1436-44. PubMed ID: 23470885
[TBL] [Abstract][Full Text] [Related]
18. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
[TBL] [Abstract][Full Text] [Related]
19. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
